Philippine News Agency
PH to increase WHO solidarity trial participants to 4K
The Department of Health (DOH) announced that the third phase of the World Health Organization (WHO) Solidarity Trial for potential COVID-19 vaccines in the Philippines is scheduled to begin in December.
The Philippines will increase the number of participants in the WHO solidarity trial to 4,000.
The WHO is expected to announce the clinical trial sites and other relevant details within the current week.
Discussions are ongoing between the Russian vaccine manufacturer Gamaleya and a Philippine contract research organization for potential local vaccine production.
Sinovac, a Chinese vaccine manufacturer, has received clearance from the Department of Science and Technology's Vaccine Expert Panel for clinical trials but still requires approval from the Ethics Board and clearance from the Food and Drug Administration.
Negotiations with US vaccine manufacturers Pfizer and Moderna are still ongoing with no confirmed details.
The Philippine government has allocated PHP2.5 billion for the procurement of COVID-19 vaccines in the proposed 2021 national budget.
Topics in this story
Explore more stories about these topics.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
The World Health Organization's Solidarity Trial Phase 3 is scheduled to commence in the Philippines in December, with the WHO expected to provide details on trial sites soon.
Read more →
Senate President Pro Tempore Ralph Recto has proposed the appointment of a "vaccine czar" by Malacañang to guarantee access to COVID-19 vaccines for 110 million Filipinos.
Read more →
The Vaccine Expert Panel (VEP) in the Philippines is currently evaluating an application from Australian firm Clover Biopharmaceuticals for COVID-19 vaccine clinical trials.
Read more →